Evidence map›Paper›PMID 31123346›Full record

ArticleBritish journal of cancer2019

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M Mannan, Brian P Rubin, George D Demetri and 9 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
  4. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

César SerranoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. cserrano@vhio.net.
Adrián Mariño-EnríquezDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
Derrick L TaoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
Julia KetzerDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Grant EilersDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
Meijun ZhuDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
Channing YuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Aristotle M MannanBroad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, USA.
Brian P RubinDepartment of Molecular Genetics, Lerner Research Institute and Cleveland Clinic, 9500, Euclid Ave, Cleveland, OH, USA.
George D DemetriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chandrajit P RautDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ajia PresnellPortland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA.
Arin McKinleyPortland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA.
Michael C HeinrichPortland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA.ORCID http://orcid.org/0000-0003-3790-0478
Jeffrey T CzaplinskiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ewa SicinskaDepartment of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
Sebastian BauerDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Suzanne GeorgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jonathan A FletcherDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. jfletcher@partners.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following:M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.The authors apologise for any convenience this may have caused.

Identifiers

PMID31123346
PMCPMC6738067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.